Travere Therapeutics Inc (TVTX) - News Archive

San Diego A New Hope in FSGS In an impressive stride for kidney disorder therapeutics, Travere Therapeutics, Inc. (Nasdaq: TVTX) has unveiled promising findings from its Phase 3 DUPLEX Study at the 2025 American Society...

: Travere Therapeutics, Inc. (Nasdaq: TVTX) is poised to make significant announcements during the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, from November 6-9. With 11 abstracts slated for pr...

Travere Therapeutics, Inc., focused on innovative therapies for rare kidney diseases, has made significant strides concerning its lead product, FILSPARI (sparsentan). Recent updates from the U.S. Food and Drug Administr...

Travere Therapeutics, Inc. (Nasdaq: TVTX), a biopharmaceutical company focused on delivering therapies for patients with rare diseases, made significant strides in research recently by presenting at the 15th Internation...

: The recent U.S. Food and Drug Administration (FDA) approval of the updated Risk Evaluation and Mitigation Strategy (REMS) for FILSPARI (sparsentan) a key therapeutic agent for IgA nephropathy (IgAN) marks a significan...

In a significant advancement for renal medicine, Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor have announced that the European Commission has granted full marketing authorization (MA) for FILSPARI (sparsentan...

Travere Therapeutics: Pioneering Advances in FSGS Treatment While Strategically Enhancing Workforce TalentIntroductionIn a landmark development, Travere Therapeutics, Inc. has submitted a supplemental New Drug Applicati...

Empowering Growth: Travere Therapeutics Bolsters Workforce with Inducement Equity Grants Amidst FDA Pursuit for FSGS TreatmentIn an exciting development, Travere Therapeutics, Inc. (NASDAQ: TVTX), a leading biopharmaceu...

Travere Therapeutics Boosts Talent Acquisition with Strategic Inducement Equity GrantsIn an aggressive push to enhance its workforce and drive innovation in the biotechnology sector, Travere Therapeutics, Inc. (NASDAQ:...

Inducement Equity Grants and Public Offering: Navigating the Strategic Financial Decisions of Travere Therapeutics, Inc.In the dynamic world of biotechnology, strategic financial and operational maneuvers mark the path...

On November 12, 2024, Travere Therapeutics, Inc. a biopharmaceutical company with a focus on developing and commercializing therapeutics for people with rare diseases, announced a significant step in bolstering its capi...

San Diego, CA In a decisive move signaling its strong position in the biopharmaceutical industry, Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced an underwritten public offering of its common stock, pricing 7,81...

Travere Therapeutics Inc. in collaboration with CSL Vifor, has officially announced that their investigational drug, FILSPARI (sparsentan), has received approval from Swissmedic for the treatment of IgA nephropathy. Thi...

In the dynamic landscape of biopharmaceutical investments, the currents of regulatory scrutiny and market performance coalesce to shape investor sentiment and corporate reputations. Recent developments surrounding Trave...

In recent tumultuous market conditions, the biotechnology sector has found itself under increased scrutiny. Among these companies is Travere Therapeutics, Inc. (NASDAQ: TVTX), which has caught the attention of Bronstein...

The biotechnology industry, characterized by its rapid innovations and significant breakthroughs, is not without its challenges. One such challenge is the scrutiny it faces from investors, regulatory bodies, and legal f...

San Diego, CA Travere Therapeutics made significant announcements recently that signal both challenges and achievements for the company as they advance their pipeline and therapeutic offerings. The company revealed a vo...

In the ever-evolving landscape of pharmaceutical sciences, one finds a beacon of hope with the recent announcement made by Travere Therapeutics, which has been resplendently graced by the full approval of FILSPARI (spar...

: Travere Therapeutics, Inc., a biopharmaceutical company focused on developing transformative therapies for serious conditions, has announced its participation in several upcoming investor conferences this August. This...

Travere Therapeutics Grants Inducement Equity Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, a leading biopharmaceutical company, recently announced the granting of inducement equity g...